Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697996 | Clinical Oncology | 2017 | 9 Pages |
Abstract
In this cohort, 67.2% of newly diagnosed glioblastoma patients had NSC involved with CELs at presentation and 95.9% at progression. This might be an imaging surrogate of the current notion of gliomagenesis and progression from NSC rests. A high radiation dose to NSC_Ipsi was significantly associated with inferior survival. This could be a function of larger tumours and planning target volumes in those with pre-treatment NSC involvement. Methylated MGMT and good compliance to adjuvant temozolomide were independent predictors of better survival. Until further evidence brings hope for glioblastoma, elective, partial NSC irradiation remains experimental.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. Achari, M. Arunsingh, R.K. Badgami, A. Saha, S. Chatterjee, R.K. Shrimali, I. Mallick, B. Arun,